Titre
The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
Type
synthèse (review)
Institution
Externe
Périodique
Auteur(s)
Rufini, V.
Auteure/Auteur
Treglia, G.
Auteure/Auteur
Perotti, G.
Auteure/Auteur
Giordano, A.
Auteure/Auteur
Liens vers les personnes
ISSN
1109-3099
Statut éditorial
Publié
Date de publication
2013
Volume
12
Numéro
1
Première page
58
Dernière page/numéro d’article
68
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
Radioiodinated metaiodobenzylguanidine (MIBG) was developed in the late 1970's, at the Michigan University Medical Center, for imaging of the adrenal medulla and its diseases. Soon after, MIBG was shown to depict a wide range of tumors of neural crest origin other than pheochromocytomas/paragangliomas (Pheo/PGL) with the result that its use rapidly spread to many countries. After more than 30 years of clinical application, MIBG continues to be the most widespread radiopharmaceutical for the functional imaging of Pheo/PGL in spite of the emergent role of PET agents for detection of these tumors. In this paper we review the evolution in the use of MIBG over more than 30 years of experimental and clinical applications, with particular focus on the uptake mechanisms, pharmacokinetics, biodistribution and drug interaction as well as on clinical studies in Pheo/PGL also in comparison to other gamma-emitters tracers and PET radiopharmaceuticals.
Sujets
PID Serval
serval:BIB_351F3905DBD3
PMID
Date de création
2017-08-20T20:10:13.988Z
Date de création dans IRIS
2025-05-20T20:46:54Z